News
AbbVie Tracking for New Highs in 2024
Shares of AbbVie (NYSE: ABBV) fell hard in the wake of its Q1 earnings report, but the dip is over. The market response to slowing Humira sales is overshadowed by strength in the non-Humira
Pfizer Finds a Foothold After a Solid Q1 2024 Earnings Report
Biopharma giant Pfizer Inc. (NYSE: PFE) has given back all its COVID gains and more. Shareholders have sat through a painful two-year selloff from the stock's $61.71 high on December 20, 2021, to
Analyst Sentiment, Revenue Growth Will Lead AbbVie Stock Higher
AbbVie Inc. (NYSE: ABBV) stock is recovering after falling over 4% in the week preceding its earnings report on April 26, 2024. As the market closed on Monday, April 29, ABBV stock posted a gain
CESI Solar Cells Fuels the Satellites of the Global Internet
MILAN, ITALY / ACCESSWIRE / April 24, 2024 / The Italian group CESI has secured a contract, with options valued at over one hundred million euros over five years, with one of the world's
Solarzellen von CESI liefern Strom für die Satelliten des globalen Internets
MAILAND, ITALIEN / ACCESSWIRE / 24. April 2024 / Die italienische Gruppe CESI hat mit einem der weltweit führenden Herstellern von Raumfahrtsystemen einen Vertrag abgeschlossen, der Optionen
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
The GLP-1 weight loss trend continues to flourish, and the ante keeps rising. The reigning champions in the battle of the bulge are Novo Nordisk A/V (NYSE: NVO) with its Semaglutide medications
Seyond's High-Performance LiDAR Technology Powers the Future of Autonomous Racing
SUNNYVALE, CA and ABU DHABI, UAE / ACCESSWIRE / April 18, 2024 / In an unprecedented leap forward for automotive technology and motorsports, Seyond, a leading global provider of image-grade
Die Hochleistungs-LiDAR-Technologie von Seyond treibt die Zukunft des autonomen Rennsports voran
SUNNYVALE, Kalifornien und ABU DHABI, Vereinigte Arabische Emirate / ACCESSWIRE / 18. April 2024 / Seyond, ein weltweit führender Anbieter von bildbasierter LiDAR-Technologie, freut sich,
Abbott Laboratories Outlook is Healthy: Buy the Dip
Abbott Laboratories' (NYSE: ABT) share price was corrected at the end of CQ1 2024 on growth, profitability and capital returns concerns. The FQ1 results, however, belie the fear and have the market
Undervalued UnitedHealth Group Won’t Be For Long
UnitedHealth Group's (NYSE: UNH) Q1 results were better than expected for two reasons: First, the stock price is now rebounding from long-term lows and deep value territory with ample upside
Johnson & Johnson is as Cheap as it’s Going to Get
Shares of Johnson & Johnson (NYSE: JNJ) are as cheap as they will get. The stock is down in premarket trading following the Q1 release, but there is a bottom in play and reality to face. Trading
Novo Nordisk Arms Wegovy to Be a Triple Threat
Ozempic usage for weight loss has gone viral, making it the highest revenue-generating drug for Novo Nordisk AV/S (NYSE: NVO). Originally purposed for Type 2 diabetes, the skyrocketing off-label
Akebia Therapeutics Surges on FDA Approval for Anemia Treatment
Akebia Therapeutics Inc. (NASDAQ: AKBA) is a biopharmaceutical company specializing in developing treatments for chronic kidney diseases (CKD) and anemia management for patients with CKD. The
Biotech Sector Nears Breakout: Will it Outperform in Q2?
The popular iShares Biotechnology ETF (NASDAQ: IBB) has formed a bullish consolidation in the upper portion of its 52-week range, hinting at a significant sector-wide breakout.
The bullish
DexCom Stock Gains from GLP-1 Diabetic Users
DexCom Inc. (NASDAQ: DXCM) is a leading medical device company in the medical sector that specializes in continuous glucose monitoring (CGM) systems. People with diabetes use CGM systems to
7 Stocks That Will Drive the Weight Loss Drugs Market
The global obesity epidemic has reached unprecedented proportions, causing severe health consequences and placing an immense economic burden on healthcare systems. Pharmaceutical companies are
COUNT Energy Trading and Corsair Group International Make Strides with Finnish Plastic Waste Advanced Recycling Plant
Collaborative efforts between COUNT and Corsair lead to Advanced Circular Feedstock (Advanced Bio-oil, Pyrolysis oil) production from daily household plastic waste, setting a new standard for
4 Oversold Large Cap Stocks Yielding High Dividends
As the market continues its relentless ascent to new heights, propelled by the surging tech sector and hype surrounding AI, the murmurs of potential interest rate cuts by the Federal Reserve
MedMira erhält kanadisches Patent für sein einzigartiges quantitatives Diagnosesystem
Halifax, Nova Scotia, 13. März 2024 - Heute gibt MedMira Inc. (MedMira) (TSXV: MIR) den Erhalt eines kanadischen Patents (Nummer 2.949.634) für sein neues innovatives und quantitatives
MedMira Receives Canadian Patent for its Unique Quantitative Diagnostic System
Halifax, Nova Scotia, March 13, 2024 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the receipt of a Canadian patent (number 2,949,634) for its new innovative and quantitative test
Eilt: Völlig neue Krebsbehandlung - Hautkrebs vollständig geheilt. Diesen Biotech Hot Stock jetzt kaufen nach 9.290% mit Novo-Nordisk ($NVO)
Eilt: Völlig neue Krebsbehandlung - Hautkrebs vollständig geheilt. Diesen Biotech Hot Stock jetzt kaufen nach 9.290%
13.03.24 08:02
London (www.aktiencheck.de, Anzeige)
Eilt: Studie für völlig neue Krebsbehandlung genehmigt. Neuer 797% Biotech Hot Stock nach 15.973% mit BioNTech ($BNTX)
Eilt: Studie für völlig neue Krebsbehandlung genehmigt. Neuer 797% Biotech Hot Stock nach 15.973% mit BioNTech ($BNTX)
12.03.24
London (www.aktiencheck.de, Anzeige)
Link
Medtronic is a Dividend Aristocrat That Keeps Gaining
Medical device maker Medtronic PLC (NYSE: MDT) is a Dividend Aristocrat in the medical and healthcare sectors. The medical device maker has raised its dividend payout for 46 consecutive years
Sensationelle Studienergebnisse - Hautkrebs vollständig geheilt. Neuer 797% Biotech Hot Stock nach 15.973% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB).
Sensationelle Studienergebnisse - Hautkrebs vollständig geheilt. 797% Biotech Hot Stock nach 10.996% mit Pfizer ($PFE)
11.03.24 08:02
London (www.aktiencheck.de, Anzeige)
5 Stocks with Unusually Large Short Interest
With the broader market reaching new all-time highs, primarily driven by the tech sector and specifically semiconductor stocks fueled by the hype surrounding AI, the spotlight is once again